[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urodynamics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urodynamics":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,82,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":48},"100625621","ambulatory-long-length-urodynamics-evaluation-100625621",false,"NCT07425015","Ambulatory Long Length URodynamics Evaluation","ALLURE","Inclusion Criteria:\n\n1. Male or female patient must be ≥ 22 years of age.\n2. Patient is a candidate for UDS per standard of care.\n3. Patient is able to provide informed consent.\n\nExclusion Criteria:\n\n1. Patient has one or more symptoms indicative of a urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and\u002For dysuria).\n2. Patient has a history of recurrent UTIs (≥ 3 episodes in previous 12 months).\n3. Patient has used antibiotics within the past 7 days from the baseline\u002Fscreening visit.\n4. Patient diagnosed with neurogenic LUTD (i.e., one or more of these conditions: normal-pressure hydrocephalus, cerebral palsy, spinal cord injuries, traumatic brain injury, stroke, Parkinson's disease, multiple sclerosis, meningomyelocele, spina bifida, dementia, Guillain-Barre syndrome, and tumors involving the central nervous systems or spine).\n5. Patient diagnosed with interstitial cystitis (IC), bladder pain syndrome, painful bladder syndrome or any etiology of chronic pelvic pain syndrome (CPPS).\n6. Patient with a urostomy.\n7. Patient with a colostomy.\n8. Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and\u002For bladder wall) that the principal investigator deems might compromise the placement or retention of the Glean sensors during the study (e.g., strictures).\n9. Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen).\n10. Patient with any abnormal or concerning rectal conditions such as ongoing anal fissures, rectocele, fistula, active herpes, or active yeast infections.\n11. Patient has a known inability to void.\n12. Patient has a previous history of radiation leading to bleeding (e.g., hemorrhagic radiation cystitis).\n13. Patient is pregnant (as confirmed by urine pregnancy test or medical history) or breastfeeding, pregnant within the past 6 months, or intending to become pregnant during the study period.\n14. Patients who may not be able to independently use a smart device.\n15. Subjects who, at the principal investigator's determination, would not be appropriate for this study.","ALL","22 Years",{"count":19,"type":20},101,"ESTIMATED","INTERVENTIONAL",[23],"NA","A prospective, open-label, single arm interventional trial evaluating the safety and performance of the in-clinic and extended monitoring of the lower urinary tract using the Glean Urodynamics System.",[26,27,28,29,30,31,32],"Urology","Urinary Bladder, Overactive","Benign Prostatic Hyperplasia","Urodynamics","Home Monitoring","Urinary Incontinence (UI)","Lower Urinary Tract Dysfunction",[34,35,36],"Bright Uro","Glean Urodynamics System","Uroflowmetry","RECRUITING","2026-04-13",{"date":40,"type":41},"2026-04-15","ACTUAL",{"date":43,"type":41},"2026-02-17",{"date":45,"type":20},"2027-06",{"name":34,"class":47},"INDUSTRY",7,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100614307","the-effect-of-virtual-reality-during-urodynamics-on-vital-signs-anxiety-and-satisfaction-100614307","NCT07277894","The Effect of Virtual Reality During Urodynamics on Vital Signs, Anxiety, and Satisfaction","The Effect of Virtual Reality During Non-Invasive Urodynamics on Patients' Vital Signs, Anxiety, and Satisfaction Levels","Inclusion Criteria:\n\n* Being the first to undergo noninvasive urodynamics;\n* Agreeing to participate in the study;\n* Being between the ages of 30-50.\n\nExclusion Criteria:\n\n* Having had a urodynamic test before;\n* Being on antidepressants or anxiolytics;\n* Having communication and cooperation problems;\n* Having visual or balance disorders.",true,"18 Years","50 Years",{"count":60,"type":20},60,[23],"Study Topic\n\nThis research aims to evaluate the effects of virtual reality (VR) application during noninvasive urodynamics on patients' vital signs, anxiety, and satisfaction levels.\n\nSignificance of the Problem\n\nUrodynamic studies are essential diagnostic methods for assessing lower urinary tract functions.\n\nHowever, they often cause discomfort, pain, and high levels of anxiety in patients.\n\nThis not only negatively affects the patient experience but also creates uncertainty in clinical decision-making.\n\nPrevious studies have shown that nursing interventions such as music therapy, aromatherapy, and heating pads effectively reduce anxiety.\n\nRecently, VR technology has emerged as a promising tool to distract patients, thereby reducing pain and anxiety.\n\nAim of the Study\n\nTo investigate the effects of VR application during noninvasive urodynamics on:\n\nVital signs,\n\nAnxiety,\n\nComfort, and\n\nPatient satisfaction.\n\nMethodology\n\nDesign: Single-center, randomized controlled clinical trial.\n\nSetting\u002FDuration: Urology Outpatient Clinic, Ankara Etlik City Hospital, September - December 2025.\n\nSample: Based on power analysis, at least 26 patients per group; total minimum of 52 participants.\n\nInclusion criteria: 18-50 years old, undergoing noninvasive urodynamics for the first time, voluntary participation.\n\nExclusion criteria: Previous urodynamics, use of anxiolytics\u002Fantidepressants, communication\u002Fvision\u002Fbalance impairments.\n\nRandomization: Block randomization (block size 6).\n\nData Collection Tools\n\nDescriptive Characteristics Form\n\nState-Trait Anxiety Inventory (STAI)\n\nVital Signs and Urodynamic Parameters Monitoring Form\n\nPatient Satisfaction and Comfort Assessment (Visual Analog Scale - VAS)\n\nVR Application Satisfaction Form\n\nInterventions\n\nVR Group: During uroflowmetry, patients will experience a 360° virtual hygienic and spacious bathroom environment via VR goggles.\n\nControl Group: Routine clinical practice only, with standard pre-procedure information.\n\nData Analysis\n\nData will be analyzed using SPSS 21.0.\n\nNormality will be tested with Kolmogorov-Smirnov.\n\nBetween-group differences will be assessed using Independent Samples t-test or Mann-Whitney U test, as appropriate.\n\nStatistical significance will be set at p \\\u003C 0.05.\n\nEthical Considerations\n\nEthical approval and hospital permission were obtained.\n\nInformed consent will be collected from all participants prior to data collection.",[64,65,29],"Urinary Incontinence","Urodynamic Studies",[67,68,69,70],"Urinary incontinence","urodynamic studies","anxiety","satisfaction","NOT_YET_RECRUITING","2025-11-29",{"date":74,"type":41},"2025-12-11",{"date":76,"type":20},"2025-12-01",{"date":78,"type":20},"2026-01-15",{"name":80,"class":81},"Saglik Bilimleri Universitesi","OTHER",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100513700","phase-4-evaluation-the-efficacy-between-botox-injection-and-combination-pharmacotherapy-in-patients-with-detrusor-overactivity-100513700","NCT05968885","Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","Evaluation of the Efficacy and Urodynamic Outcomes Between Intradetrusor onabotulinumtoxinA Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with either anti-muscarinics or β3-adrenoceptor agonists were enrolled for prospective study\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment","FEMALE","20 Years","90 Years",{"count":93,"type":20},300,[95],"PHASE4","To investigates the effects of botulinum toxin type A bladder injection compared to combined pharmacotherapy with Mirabegron and Solifenacin.",[27,29,98],"Effect of Drug",[100,101,102,103,104],"Detrusor overactivity","Urodynamic study","Combined pharmacotherapy","Botulinum Toxins","Effectiveness","2025-05-06",{"date":107,"type":41},"2025-05-09",{"date":109,"type":41},"2021-10-01",{"date":111,"type":20},"2026-12-31",{"name":113,"class":81},"Mackay Memorial Hospital",1,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":122,"minAge":57,"maxAge":91,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100582500","urodynamics-prone-vs-seated-position-100582500","NCT06864117","Urodynamics: Prone Vs. Seated Position","Comparison of Urine Flow Measurements in the Context of Pressure Flow Studies in Men in Supine and Sitting Positions Using a Urinary Condom","Inclusion Criteria:\n\n* Genotype and phenotype XY\n* Age between 18 and 90 years\n* Signed informed consent form\n* Ability to understand and follow the study procedures and understand the consent form\n* possibility ti carry out out the necessary urodynamics as part of the regular clinical examination\n* assessment of neurogenic and\u002For non-neurogenic (idiopathic) bladder dysfunction\n* Spontaneous micturition in a sitting position is possible\n\nExclusion criteria:\n\n* Patients with assistance\u002Fpatients under guardianship\n* Patients with latex allergy or cross-allergy (banana, kiwi, fig, avocado)\n* No spontaneous movement possible in a sitting position\n* Sitting position not possible due to lack of trunk stability\u002Fcirculatory problems\n* Intravesical Botox injection during the last 9 months","MALE",{"count":124,"type":20},200,[23],"To demonstrate the feasibility of a pressure-flow study using a urinary condom with drainage tube in the sitting and lying position in everyday clinical practice and the comparability of the measured values with the \"conventional\" pressure-flow studies according to the ICS standard with regard to the diagnosis of outlet obstruction in men.",[65,29,128],"Outlet Obstruction",[130,131],"obstruction","urodynamics","2025-03-03",{"date":134,"type":41},"2025-03-07",{"date":136,"type":20},"2025-02-28",{"date":138,"type":20},"2028-02-28",{"name":140,"class":81},"Kantonsspital Winterthur KSW"]